Cell Cycle Variants and Metastatic Prostate Cancer Risk

细胞周期变异和转移性前列腺癌风险

基本信息

  • 批准号:
    6859610
  • 负责人:
  • 金额:
    $ 24.17万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2005
  • 资助国家:
    美国
  • 起止时间:
    2005-04-08 至 2010-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): PSA based screening has contributed to a dramatic increase in the number of prostate cancer cases and to a recent fall in mortality from the disease. However, this success has come at a cost: over-diagnosis and over-treatment for some and ineffectual treatment for others. Since upwards of 80% of men develop histologic prostate cancer, the critical question in 2004 is not who is at risk for developing prostate cancer, but who is at risk for developing lethal prostate cancer. Identification of those men at high risk for aggressive and potentially lethal prostate carcinoma prior to diagnosis would allow intense screening and/or prophylaxis while spading individuals at low risk years of screening. Identification of high risk patients at the time of diagnosis would target individuals for aggressive therapy while sparing those at low risk from potentially morbid treatment. Since it has been hypothesized that metastatic potential is determined at least in part by host genetic background, it follows that analysis of common polymorphic variants will prove to be a useful screening tool to determine who is at risk for lethal prostate carcinoma. We propose to perform a case control study to identify susceptibility loci for metastatic disease and then to validate our findings in additional cohorts including a prospectively acquired patient population. We have chosen genes in the cell cycle as our candidates because there are abundant data demonstrating 1) subtle genomic changes in cell cycle genes increase risk of cancer in animal models, 2) variants alter gene function in cell cycle genes and lastly 3) genetic variants within cell cycle genes are associated with aggressive prostate carcinoma. The three specific aims of this proposal are: (I) To search for associations between polymorphisms in cell cycle regulatory genes and increased risk of metastatic prostate carcinoma. (2) To determine if risk alleles identified in Aim 1 are predictors of metastatic prostate carcinoma specifically or prostate cancer in general by studying additional patient populations. (3) To establish a prospective cohort to determine if high risk SNPs are predictive of risk for treatment failure. At the conclusion of this study, we will have a panel of markers that can be used to predict which patients are at high risk of treatment failure and eventual death from prostate carcinoma.
描述(由申请人提供):基于PSA的筛查导致前列腺癌病例数量的急剧增加,并导致该疾病的死亡率最近下降。然而,这一成功是有代价的:一些人过度诊断和过度治疗,另一些人治疗无效。由于超过80%的男性患有组织学前列腺癌,2004年的关键问题不是谁有患前列腺癌的风险,而是谁有患致命性前列腺癌的风险。在诊断前确定那些具有侵袭性和潜在致命性前列腺癌高风险的男性,可以进行密集的筛查和/或预防,同时分散低风险个体的筛查年限。在诊断时识别高风险患者将针对个体进行积极治疗,同时使低风险患者免于潜在的病态治疗。由于已经假设转移潜能至少部分由宿主遗传背景决定,因此对常见多态性变异的分析将被证明是确定谁有致死性前列腺癌风险的有用筛查工具。我们建议进行一项病例对照研究,以确定转移性疾病的易感性位点,然后在其他队列(包括前瞻性获得的患者群体)中验证我们的发现。我们选择细胞周期中的基因作为我们的候选基因,因为有大量的数据表明:1)在动物模型中,细胞周期基因中细微的基因组变化增加了癌症的风险;2)变异改变了细胞周期基因中的基因功能;最后3)细胞周期基因中的遗传变异与侵袭性前列腺癌有关。本提案的三个具体目的是:(1)寻找细胞周期调节基因多态性与转移性前列腺癌风险增加之间的关联。(2)通过研究额外的患者群体,确定Aim 1中确定的风险等位基因是转移性前列腺癌的特异性预测因子还是前列腺癌的总体预测因子。(3)建立前瞻性队列,以确定高风险snp是否可预测治疗失败风险。在这项研究的结论,我们将有一组标志物,可用于预测哪些患者在治疗失败和最终死亡的高风险前列腺癌。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ADAM S KIBEL其他文献

ADAM S KIBEL的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ADAM S KIBEL', 18)}}的其他基金

Polygenic risk stratification combined with mpMRI to identify clinically relevant prostate cancer
多基因风险分层结合 mpMRI 来识别临床相关的前列腺癌
  • 批准号:
    10610626
  • 财政年份:
    2023
  • 资助金额:
    $ 24.17万
  • 项目类别:
Cell Cycle Variants and Metastatic Prostate Cancer Risk
细胞周期变异和转移性前列腺癌风险
  • 批准号:
    7051995
  • 财政年份:
    2005
  • 资助金额:
    $ 24.17万
  • 项目类别:
Cell Cycle Variants and Metastatic Prostate Cancer Risk
细胞周期变异和转移性前列腺癌风险
  • 批准号:
    7560021
  • 财政年份:
    2005
  • 资助金额:
    $ 24.17万
  • 项目类别:
Cell Cycle Variants and Metastatic Prostate Cancer Risk
细胞周期变异和转移性前列腺癌风险
  • 批准号:
    7344737
  • 财政年份:
    2005
  • 资助金额:
    $ 24.17万
  • 项目类别:
Cell Cycle Variants and Metastatic Prostate Cancer Risk
细胞周期变异和转移性前列腺癌风险
  • 批准号:
    7198099
  • 财政年份:
    2005
  • 资助金额:
    $ 24.17万
  • 项目类别:
Genetic Risk Profiling in Metastatic Prostate Carcinoma
转移性前列腺癌的遗传风险分析
  • 批准号:
    6556523
  • 财政年份:
    2003
  • 资助金额:
    $ 24.17万
  • 项目类别:
Genetic Risk Profiling in Metastatic Prostate Carcinoma
转移性前列腺癌的遗传风险分析
  • 批准号:
    6722907
  • 财政年份:
    2003
  • 资助金额:
    $ 24.17万
  • 项目类别:
IDENTIFICATION OF A 12P PROSTATE TUMOR SUPPRESSOR GENE
12P 前列腺肿瘤抑制基因的鉴定
  • 批准号:
    6232986
  • 财政年份:
    2001
  • 资助金额:
    $ 24.17万
  • 项目类别:
IDENTIFICATION OF A 12P PROSTATE TUMOR SUPPRESSOR GENE
12P 前列腺肿瘤抑制基因的鉴定
  • 批准号:
    6514864
  • 财政年份:
    2001
  • 资助金额:
    $ 24.17万
  • 项目类别:
IDENTIFICATION OF A 12P PROSTATE TUMOR SUPPRESSOR GENE
12P 前列腺肿瘤抑制基因的鉴定
  • 批准号:
    6633919
  • 财政年份:
    2001
  • 资助金额:
    $ 24.17万
  • 项目类别:

相似海外基金

FAIRClinical: FAIR-ification of Supplementary Data to Support Clinical Research
FAIRClinical:补充数据的 FAIR 化以支持临床研究
  • 批准号:
    EP/Y036395/1
  • 财政年份:
    2024
  • 资助金额:
    $ 24.17万
  • 项目类别:
    Research Grant
Optimizing integration of veterinary clinical research findings with human health systems to improve strategies for early detection and intervention
优化兽医临床研究结果与人类健康系统的整合,以改进早期检测和干预策略
  • 批准号:
    10764456
  • 财政年份:
    2023
  • 资助金额:
    $ 24.17万
  • 项目类别:
The IDeA State Consortium for a Clinical Research Resource Center: Increasing Clinical Trials in IDeA States through Communication of Opportunities, Effective Marketing, and WorkforceDevelopment
IDeA 州临床研究资源中心联盟:通过机会交流、有效营销和劳动力发展增加 IDeA 州的临床试验
  • 批准号:
    10715568
  • 财政年份:
    2023
  • 资助金额:
    $ 24.17万
  • 项目类别:
The Mayo Clinic NeuroNEXT Clinical Research Site
梅奥诊所 NeuroNEXT 临床研究网站
  • 批准号:
    10743328
  • 财政年份:
    2023
  • 资助金额:
    $ 24.17万
  • 项目类别:
Addressing Underperformance in Clinical Trial Enrollments: Development of a Clinical Trial Toolkit and Expansion of the Clinical Research Footprint
解决临床试验注册表现不佳的问题:开发临床试验工具包并扩大临床研究足迹
  • 批准号:
    10638813
  • 财政年份:
    2023
  • 资助金额:
    $ 24.17万
  • 项目类别:
The Minnesota TMD IMPACT Collaborative: Integrating Basic/Clinical Research Efforts and Training to Improve Clinical Care
明尼苏达州 TMD IMPACT 协作:整合基础/临床研究工作和培训以改善临床护理
  • 批准号:
    10828665
  • 财政年份:
    2023
  • 资助金额:
    $ 24.17万
  • 项目类别:
Improving Multicultural Engagement in Clinical Research through Partnership with Federally Qualified Health Centers and Community Health Worker Programs
通过与联邦合格的健康中心和社区卫生工作者计划合作,改善临床研究中的多元文化参与
  • 批准号:
    10823828
  • 财政年份:
    2023
  • 资助金额:
    $ 24.17万
  • 项目类别:
Promoting a Culture Of Innovation, Mentorship, Diversity and Opportunity in NCI Sponsored Clinical Research: NCI Research Specialist (Clinician Scientist) Award Application of Janice M. Mehnert, M.D.
在 NCI 资助的临床研究中促进创新、指导、多样性和机会文化:Janice M. Mehnert 医学博士的 NCI 研究专家(临床科学家)奖申请
  • 批准号:
    10721095
  • 财政年份:
    2023
  • 资助金额:
    $ 24.17万
  • 项目类别:
Clinical Research Center for REstoration of NEural-based Function in the Real World (RENEW)
现实世界神经功能恢复临床研究中心 (RENEW)
  • 批准号:
    10795328
  • 财政年份:
    2023
  • 资助金额:
    $ 24.17万
  • 项目类别:
Mentoring Scientists for Careers in HIV Translational Clinical Research
指导科学家从事艾滋病毒转化临床研究
  • 批准号:
    10762827
  • 财政年份:
    2023
  • 资助金额:
    $ 24.17万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了